AbCellera Biologics Inc.
ABCL
$3.65
$0.082.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 44.85M | 8.96M | 17.08M | 4.24M | 5.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.85M | 8.96M | 17.08M | 4.24M | 5.05M |
| Cost of Revenue | 50.09M | 55.03M | 39.21M | 42.50M | 46.08M |
| Gross Profit | -5.24M | -46.07M | -22.13M | -38.26M | -41.03M |
| SG&A Expenses | 17.22M | 24.96M | 21.99M | 19.07M | 19.16M |
| Depreciation & Amortization | 6.12M | 5.25M | 5.47M | 5.33M | -19.44M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.44M | 85.23M | 66.67M | 66.90M | 45.81M |
| Operating Income | -28.58M | -76.28M | -49.59M | -62.66M | -40.76M |
| Income Before Tax | -19.50M | -68.77M | -36.34M | -52.98M | -46.83M |
| Income Tax Expenses | -10.55M | -11.65M | -1.62M | -7.36M | -12.62M |
| Earnings from Continuing Operations | -8.95M | -57.12M | -34.73M | -45.62M | -34.21M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.95M | -57.12M | -34.73M | -45.62M | -34.21M |
| EBIT | -28.58M | -76.28M | -49.59M | -62.66M | -40.76M |
| EBITDA | -22.46M | -71.03M | -44.11M | -57.33M | -26.04M |
| EPS Basic | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 |
| Normalized Basic EPS | -0.04 | -0.14 | -0.08 | -0.11 | -0.06 |
| EPS Diluted | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 |
| Normalized Diluted EPS | -0.04 | -0.14 | -0.08 | -0.11 | -0.06 |
| Average Basic Shares Outstanding | 299.73M | 298.88M | 298.51M | 297.69M | 295.52M |
| Average Diluted Shares Outstanding | 299.73M | 298.88M | 298.51M | 297.69M | 295.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |